Published in final edited form as:

JAMA Neurol. 2013 June ; 70(6): 772–773. doi:10.1001/jamaneurol.2013.1502.

DNA A β 42 Vaccination as Possible Alternative Immunotherapy for Alzheimer Disease

Roger N. Rosenberg, MD and Doris Lambracht-Washington, PhD

Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas.

Immunotherapy for Alzheimer disease was advanced in reports^{1,2} showing that the use of A β 42 peptide vaccination in a transgenic mouse model of Alzheimer disease significantly reduced the A β 42 plaque count, significantly reduced levels of gliosis, and significantly improved behavior. Based on the positive experimental animal model data, a human A β 42 peptide immunization clinical trial [ie, the AN1792(QS-21)-201 trial]³ for patients with Alzheimer disease was conducted; however, it was stopped owing to significant adverse effects in 6% of immunized patients. Subsequent studies showed that there were significant reductions in A β 42-containing plaque in the brain but that the patients continued to become more demented.⁴ For patients with mild Alzheimer disease, the use of passive immunotherapy with the humanized monoclonal antibody bapineuzumab resulted in no significant clinical benefit, but the use of passive immunotherapy with the humanized monoclonal antibody solanezumab resulted in some memory and behavioral benefits (*New York Times*, July 24, 2012). Intravenous immunoglobulins, which probably contain anti-A β antibodies, have also been used to treat patients with Alzheimer disease, and their use has resulted in clinical stabilization.⁵

Two new passive immuno-therapy studies are now moving forward to determine whether therapy introduced earlier in the disease process will prove to be beneficial. The Dominantly Inherited Alzheimer Network will use 2 monoclonal antibodies (gantenerumab and solanezumab) and a β -secretase inhibitor, and the Alzheimer Preventive Initiative will study the monoclonal antibody crenezumab in patients with autosomal dominant presenilin 1 mutations. Patients who are carriers of the presenilin 1 mutation and who are asymptomatic will be selected, with therapy being initiated at least 15 years before the mean age at onset of disease in their families. This early-onset date was determined from cerebrospinal fluid studies of patients in the Dominantly Inherited Alzheimer Network who showed reductions of A β levels in cerebrospinal fluid samples as early as 25 years before the mean age at onset of dementia in their families.⁶ It is hoped that patients beginning immunotherapy as early as

© 2013 American Medical Association. All rights reserved.

Correspondence: Dr Rosenberg, Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9036 (roger.rosenberg@utsouthwestern.edu).

Author Contributions: *Study concept and design:* Rosenberg. *Acquisition of data:* Lambracht-Washington. *Drafting of the manuscript:* All authors.

Conflict of Interest Disclosures: Dr Rosenberg received a Clinical Trials grant from Pfizer, Novartis, and Janssen and received a US patent for “Amyloid- β Gene Vaccines” as inventor.

15 years before dementia begins in their families will avoid the secondary downstream independent pathologies of Alzheimer disease that can continue even if the level of A β is successfully reduced, leading to progressive disease with neuronal loss, gliosis, and dementia unresponsive to immunotherapy in the later stages of disease.

Antiamyloid immunotherapy can lead to inflammation with edema, demyelination, infarction, and microbleeds, as occurred in the patients in the A β 42 peptide study [ie, the AN1792(QS-21)-201 trial].³ We have used a DNA-based immunization approach in which the immunization agent is DNA encoding the A β 1-42 trimer (3 copies of A β 1-42), which produces a noninflammatory immune response.⁷⁻⁹ DNA immunization using the gene-gun delivery into the skin results in a strongly polarized immune response that greatly differs from a peptide-generated immune response.^{10,11} A β 42 DNA vaccination via the gene gun generates a T_H2 cellular noninflammatory immune response. We have also shown that in vitro T-cell proliferation in response to A β 1-42 peptide restimulation was absent in full-length DNA trimer (3 copies of the A β 42 DNA) immunized mice, thus indicating the safety of this approach.¹⁰⁻¹²

Our report on the gene-gun–delivered DNA A β 42 immunization, with a constitutive heterologous promoter that induced a good antibody response against A β 42 in Balb/cJ mice, was the first to show that it is possible to use this method as an alternative to A β 42 peptide immunization. With the same plasmid system, we further demonstrated that prophylactic DNA A β 42 immunization in APP^{swe}/PSEN 1 δ E9 transgenic mice reduced the brain A β 42 plaque load by 42% and, furthermore, that DNA immunization with this human A β 42 sequence also lead to good antibody production in a monkey that we had tested.^{8,9} The humoral response to DNA A β 1-42 immunization was substantially improved using a binary Gal4/UAS system in combination with a novel A β 1-42 trimer construct. A β 42 trimer DNA vaccination of wild-type mice resulted in greatly increased antibody levels showing a polarized T_H2 bias (IgG1 antibodies only) with no associated T-cell response, whereas a mixed T_H1/T_H2 (IgG1/IgG2a antibodies) immune response was found in A β 42 peptide immunized mice, which were analyzed in parallel with the production of IFN- γ and IL-17 indicative of a potentially inflammatory cellular immune response.¹⁰⁻¹²

To further increase the level of antibody response with DNA immunization, we have developed a prime-boost protocol. The first immunizations initiate the immune response, and the following immunizations lead to an expansion of antigen-specific cells, with the selection of antibody-producing cells that have high antigen avidity and that lead to a boost of the specific response. We have analyzed 2 different boost regimens: the peptide boost of a DNA-primed immune response and the DNA boost of a peptide-primed immune response. To our knowledge, this is the first time that a DNA boost was shown to have such a strong effect on the developing immune response. We were able to increase the antibody levels in plasma to 250 μ g/mL with the peptide-primed/DNA boost method. Furthermore, peptide-primed/ DNA boost immunization did not result in A β 42-specific T-cell proliferation in these mice, nor did it lead to the production of inflammatory cytokines. Thus, the combination of peptide-primed/DNA boost immunization with our second-generation binary Gal4/A β 42 trimer vaccine resulted in high levels of anti-A β 42 antibodies that are polarized to a noninflammatory T_H2 cellular immune response with no T-cell proliferation and with

no production of inflammatory cytokines. As therapy, it has the potential to delay or prevent Alzheimer disease if administered early in the disease process.¹³

If passive immunotherapy is shown to provide clinical benefit by reducing A β plaque levels, is nontoxic, and delays or prevents the development of Alzheimer disease, then interest in active DNA A β 42 vaccination therapy will increase because DNA vaccination is less expensive, possibly longer lasting, and easier to administer to large populations at risk for Alzheimer disease than passive immunotherapy, which requires expensive humanized anti-A β 42 monoclonal antibodies. Using cerebrospinal fluid bio-markers and brain amyloid imaging, it is now possible to identify asymptomatic persons at risk for Alzheimer disease, and these at-risk persons offer us the best opportunity to study how passive immunotherapy delays or prevents the disease from occurring. Thus, active vaccination with the DNA A β 42 vaccine may become the method that will provide clinical benefit.^{14,15}

Acknowledgments

Funding/Support: This work was supported by the Alzheimer's Disease Center (National Institutes of Health/National Institute on Aging grant P30 AG12300-17), the Rudman Partnership, and the McCune Foundation.

REFERENCES

1. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature*. 1999; 400(6740):173–177. [PubMed: 10408445]
2. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. *Nature*. 2000; 408(6815):979–982. [PubMed: 11140685]
3. Gilman S, Koller M, Black RS, et al. AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. *Neurology*. 2005; 64(9):1553–1562. [PubMed: 15883316]
4. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. *Lancet*. 2008; 372(9634):216–223. [PubMed: 18640458]
5. Relkin, N.; Bettger, L.; Tsakanikas, D.; Ravdin, L. Three-year follow-up on the IVIG for Alzheimer's phase II study.. Alzheimer's Association International Conference; Vancouver, British Columbia, Canada. July 14-19, 2012; Abstract P3-381
6. Bateman RJ, Xiong C, Benzinger TL, et al. Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med*. 2012; 367(9):795–804. [PubMed: 22784036]
7. Qu BX, Rosenberg RN, Li L, Boyer PJ, Johnston SA. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. *Arch Neurol*. 2004; 61(12):1859–1864. [PubMed: 15596606]
8. Qu BX, Boyer PJ, Johnston SA, Hynan LS, Rosenberg RN. Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. *J Neurol Sci*. 2006; 244(1-2):151–158. [PubMed: 16556449]
9. Qu BX, Xiang Q, Li L, Johnston SA, Hynan LS, Rosenberg RN. Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. *J Neurol Sci*. 2007; 260(1-2):204–213. [PubMed: 17574274]
10. Qu BX, Lambracht-Washington D, Fu M, Eagar TN, Stüve O, Rosenberg RN. Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease. *Vaccine*. 2010; 28(32):5280–5287. [PubMed: 20562015]

11. Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stüve O, Rosenberg RN. DNA beta-amyloid (1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. *JAMA*. 2009; 302(16):1796–1802. [PubMed: 19861672]
12. Lambracht-Washington D, Qu BX, Fu M, et al. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation. *Cell Mol Neurobiol*. 2011; 31(6):867–874. [PubMed: 21625960]
13. Lambracht-Washington D, Qu BX, Fu M, et al. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation A β 42 DNA vaccine for Alzheimer's disease. *J Neuroimmunol*. 2013; 254(1-2):63–68. [PubMed: 23036592]
14. Lambracht-Washington D, Rosenberg RN. Active DNA A β 42 vaccination as immunotherapy for Alzheimer disease. *Translational Neurosci*. 2012; 3(4):307–313.
15. Rosenberg RN. Translational research on the way to effective therapy for Alzheimer disease. *Arch Gen Psychiatry*. 2005; 62(11):1186–1192. [PubMed: 16275806]